Rapid fluorescence-based reporter-gene assays to evaluate the cytotoxicity and antitumor drug potential of platinum complexes

Chemistry and Biology

Volumn 6, Issue 8, 1999, Pages 541-551

  Sandman, Karen E ^a   Marla, Sudhakar S ^a   Zlokarnik, Gregor ^b   Lippard, Stephen J ^a  

^a MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

^b Aurora Biosciences Corporation   (United States)

Author keywords

Cisplatin; Gene expression enhancement and inhibition; Genotoxic agents; Screening; Transcription

Indexed keywords

EID: 0033179662     PISSN: 10745521     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1074-5521(99)80086-6     Document Type: Article

References (58)

1. Pil, P. & Lippard, S.J. (1997). Cisplatin and related drugs. In Encyclopedia of Cancer. (Bertino, J.R., ed.), pp. 392-410, Academic Press, San Diego, CA.
2. Sandman, K.E., Fuhrmann, P. & Lippard, S.J. (1998). A mechanism-based, solution phase method for screening combinatorial mixtures of potential platinum anticancer drugs. J. Biol. Inorg. Chem. 3, 74-80.
3. Sandman, K.E. & Lippard, S.J. (1999). Methods for screening the potential antitumor activity of platinum compounds in combinatorial libraries. In 30 Years of Cisplatin - Chemistry and Biochemistry of a Leading Anticancer Drug. (Lippert, B., ed.), pp. 523-536, Verlag Helvetica Chimica Acta, Basel.
4. Borenfreund, E., Babich, H. & Martin-Alguacil, N. (1990). Rapid chemosensitivity assay with human normal and tumor cells in vitro. In Vitro Cell. Dev. Biol. 26, 1030-1034.
5. Perez, R.P., Godwin, A.K., Handel, L.M. & Hamilton, T.C. (1993). A comparison of clonogenic, microtetrazolium and sulforhodamine B assays for determination of cisplatin cytotoxicity in human ovarian carcinoma cell lines. Eur. J. Cancer 29A, 395-399.
6. Fricker, S.P. & Buckley, R.G. (1996). Comparison of two colorimetric assays as cytotoxicity endpoints for an in vitro screen for antitumour agents. Anticancer Res. 16, 3755-3760.
7. Harder, H.C. & Rosenberg, B. (1970). Inhibitory effects of anti-tumor platinum compounds on DNA, RNA and protein syntheses in mammalian cells in vitro. Int. J. Cancer 6, 207-216.
8. Pinto, A.L. & Lippard, S.J. (1985). Sequence-dependent termination of in vitro DNA synthesis by cis- and trans-diamminedichloroplatinum(II). Proc. Natl Acad. Sci. USA 82, 4616-4619.
9. Bernges, F. & Holler, E. (1988). Effects of coordination of diammineplatinum(II) with DNA on the activities of Escherichia coli DNA polymerase I. Biochemistry 27, 6398-6402.
10. Mello, J.A., Lippard, S.J. & Essigmann, J.M. (1995). DNA adducts of cis-diamminedichloroplatinum(II) and its trans isomer inhibit RNA polymerase II differentially in vivo. Biochemistry 34, 14783-14791.
11. Evans, G.L. & Gralla, J.D. (1992). Differential effects of cisplatin on the expression of chimeric marker genes in CV-1 cells. Biochem. Pharm. 44, 107-119.
12. Mymryk, J.S., Zaniewski, E. & Archer, T.K. (1995). Cisplatin inhibits chromatin remodeling, transcription factor binding, and transcription from the mouse mammary tumor virus promoter in vivo. Proc. Natl Acad. Sci. USA 92, 2076-2080.
13. Takahara, P.M., Rosenzweig, A.C., Frederick, C.A. & Lippard, S.J. (1995). Crystal structure of double-stranded DNA containing the major adduct of the anticancer drug cisplatin. Nature 377, 649-652.
14. Dunham, S.U., Dunham, S.U., Turner, C.J. & Lippard, S.J. (1998). Solution structure of a DNA duplex containing a nitroxide spin-labeled platinum d(GpG) intrastrand cross-link refined with NMR-derived long-range electron-proton distance restraints. J. Am. Chem. Soc. 120, 5395-5406.
15. Gelasco, A. & Lippard, S.J. (1998). NMR solution structure of a DNA dodecamer duplex containing a cis-diammineplatinum(ii) d(GpG) intrastrand cross-link, the major adduct of the anticancer drug cisplatin. Biochemistry 37, 9230-9239.
16. Smith, M.L. & Fornace, A.J. (1996). Mammalian DNA damage-inducible genes associated with growth arrest and apoptosis. Mutat. Res. 340, 109-124.
17. Smith, M.L. & Fornace, A.J. (1997). P53-mediated protective responses to UV irradiation. Proc. Natl Acad. Sci. USA 94, 12255-12257.
18. Eliopoulos, A., Kerr, D.J. & Spandidos, D.A. (1991). The effect of cisplatin and carboplatin on c-myc promoter in erythroleukemic cells. Anti-Cancer Drugs 2, 597-601.
19. Niimi, S., et al., & Saijo, N. (1991). Resistance to anti-cancer drugs in NIH3T3 cells transfected with c-myc and/or c-Ha-ras genes. Br. J. Cancer 63, 237-241.
20. Rabo, Y.B., Shoshan, M.C., Linder, S. & Hansson, J. (1996). Different mechanisms are responsible for c-jun mRNA induction by cisplatin and ultraviolet light. Int. J. Cancer 65, 821-826.
21. Scanlon, K.J., Kashani-Sabet, M., Tone, T. & Funato, T. (1991). Cisplatin resistance in human cancers. Phamacol. Ther. 52, 385-406.
22. Evans, G.L. & Gralla, J.D. (1992). Cisplatin-induced imbalances in the pattern of chimeric marker gene expression in HeLa cells. Biochem. Biophys. Res. Comm. 184, 1-8.
23. Zoumpourlis, V., Kerr, D.J. & Spandidos, D.A. (1992). Carboplatin as opposed to cisplatin does not stimulate the expression of the human immunodeficiency virus long terminal repeat sequences. Biochem. Pharmacol. 43, 650-654.
24. Valerie, K., Delers, A., Bruck, C., Thiriart, C., Rosenberg, H., Debouck, C. & Rosenberg, M. (1988). Activation of human immunodeficiency virus type 1 by DNA damage in human cells. Nature 333, 78-81.
25. Schaefer, E.L., Morimoto, R.I., Theodorakis, N.G. & Seidenfeld, J. (1988). Chemical specificity for induction of stress response genes by DNA-damaging drugs in human adenocarcinoma cells. Carcinogenesis 9, 1733-1738.
26. Collins, L.A., Torrero, M.N. & Franzblau, S.G. (1998). Green fluorescent protein reporter microplate assay for high-throughput screening of compounds against Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 42, 344-347.
27. Fink, D., et al., & Howell, S.B. (1998). The effect of different chemotherapeutic agents on the enrichment of DNA mismatch repair-deficient tumour cells. Br. J. Cancer 77, 703-708.
28. Cubitt, A.B., Heim, R., Adams, S.R., Boyd, A.E., Gross, L.A. & Tsien, R.Y. (1995). Understanding, improving and using green fluorescent proteins. Trends Biochem. 20, 448-455.
29. Coxon, A. & Bestor, T.H. (1995). Proteins that glow in green and blue. Chem. Biol. 2, 119-121.
30. Chalfie, M. (1995). Green fluorescent protein. Photochem. Photobiol. 62, 651-656.
31. Zlokarnik, G., et al., & Tsien, R.Y. (1998). Quantitation of transcription and clonal selection of single living cells with β-lactamase as reporter. Science 279, 84-88.
32. ClonTechniques XIII (1998). Living colors destabilized EGFP vectors.
33. Freundlieb, S., Baron, U., Bonin, A.L., Gossen, M. & Bujard, H. (1997). Use of tetracycline-controlled gene expression systems to study mammalian cell cycle. Methods Enzymol. 283, 159-173.
34. Boreham, D.R., Dolling, J.-A., Maves, S.R., Miller, S., Morrison, D.P. & Mitchel, R.E.J. (1997). Heat-induced thermal tolerance and radiation resistance to apoptosis in human lymphocytes. Biochem. Cell Biol. 75, 393-397.
35. L overexpression restricts heat-induced apoptosis and influences hsp70, bcl-2, and Bax protein levels in FL5.12 cells. Biochem. Biophys. Res. Comm. 241, 164-168.
36. Kuo, M.-L, Chou, Y.-W., Chau, Y.-P. & Meng, T.-C. (1996). Differential induction of apoptosis in oncogene-transformed NIH 3T3 cells by methylmethanesulfonate. Biochem. Pharmacol. 52, 481-488.
37. O'Neill, C.F., Ormerod, M.G., Robertson, D., Titley, J.C., Cumber-Walsweer, Y. & Kelland, L.R. (1996). Apoptotic and non-apoptotic cell death induced by cis and trans analogues of a novel ammine(cyclohexylamine)dihydroxodichloro-platinum (IV) complex. Br. J. Cancer 74, 1037-1045.
38. Morimoto, R.I., et al., & Sistonen, L.T. (1994). Regulation of heat shock gene transcription by a family of heat shock factors. In The Biology of Heat Shock Proteins and Molecular Chaperones. (Morimoto, R.I., Tissiere, A. & Georgopoulos, C., eds) pp. 417-455. Cold Spring Harbor Laboratory Press, Cold Spring Harbor.
39. Potapova, O., et al., & Mercola, D. (1997). The Jun kinase/stress-activated protein kinase pathway functions to regulate DNA repair and inhibition of the pathway sensitizes tumor cells to cisplatin. J. Biol. Chem. 272, 14041-14044.
40. Sanchez-Perez, I., Murguia, J.R. & Perona, R. (1998). Cisplatin induces a persistent activation of JNK that is related to cell death. Oncogene 16, 533-540.
41. Nicolaou, K.C., Stabila, P., Esmaeli-Azad, B., Wrasidlo, W. & Hiatt, A. (1993). Cell-specific regulation of apoptosis by designed enediynes. Proc. Natl Acad. Sci. USA 90, 3142-3146.
42. Nicolaou, K.C., Pitsinos, E.N., Theodorakis, E.A., Saimoto, H. & Wrasidlo, W. (1994). Synthetic calicheamicin mimics with novel initiation mechanisms: DNA cleavage, cytotoxicity, and apoptosis. Chem. Biol. 1, 57-66.
43. Zamble, D.B., Mu, D., Reardon, J.T., Sancar, A. & Lippard, S.J. (1996). Repair of cisplatin-DNA adducts by the mammalian excision nuclease. Biochemistry 35, 10004-10013.
44. Toney, J.H., Donahue, B.A., Kellett, P.J., Bruhn, S.L., Essigmann, J.M. & Lippard, S.J. (1989). Isolation of cDNAs encoding a human protein that binds selectively to DNA modified by the anticancer drug cis-diamminedichloroplatinum(II). Proc. Natl Acad. Sci. USA 86, 8328-8332.
45. Bruhn, S.L., Toney, J.H. & Lippard, S.J. (1990). Biological processing of DNA modified by platinum compounds. Prog. Inorg. Chem. 38, 477-516.
46. Coin, F., Frit, P., Viollet, B., Salles, B. & Egly, J.-M. (1998). TATA binding protein discriminates between different lesions on DNA, resulting in a transcription decrease. Mol. Cell. Biol. 18, 3907-3914.
47. Zlatanova, J., Yaneva, J. & Leuba, S.H. (1998). Proteins that specifically recognize cisplatin-damaged DNA: A clue to anticancer activity of cisplatin. FASEB J. 12, 791-799.
48. Hansson, J., Grossman, L., Lindahl, T. & Wood, R.D. (1990). Complementation of the xeroderma pigmentosum DNA repair synthesis defect with Escherichia coli UvrABC proteins in a cell-free system. Nucleic Acids Res. 18, 35-40.
49. Glaab, W.E., Risinger, J.I., Umar, A., Barrett, J.C., Kunkel, T.A. & Tindall, K.R. (1998). Cellular resistance and hypermutability in mismatch repair-deficient human cancer cell lines following treatment with methyl methanesulfonate. Mutat. Res. 398, 197-207.
50. Brown, S.J., Kellett, P.J. & Lippard, S.J. (1993). Ixr1, a yeast protein that binds to platinated DNA and confers sensitivity to cisplatin. Science 261, 603-605.
51. Huang, J.-C., Zamble, D.B., Reardon, J.T., Lippard, S.J. & Sancar, A. (1994). HMG-domain proteins specifically inhibit the repair of the major DNA adduct of the anticancer drug cisplatin by human excision nuclease. Proc. Natl Acad. Sci. USA 91, 10394-10398.
52. McA'Nulty, M.M. & Lippard, S.J. (1996). The HMG-domain protein Ixr1 blocks excision repair of cisplatin-DNA adducts in yeast. Mutat. Res. 362, 75-86.
53. Donahue, B.A., et al., & Essigmann, J.M. (1990). Characterization of a DNA damage-recognition protein from mammalian cells that binds specifically to intrastrand d(GpG) and d(ApG) DNA adducts of the anticancer drug cisplatin. Biochemistry 29, 5872-5880.
54. Treiber, D.K., Zhai, X., Jantzen, H.-M. & Essigmann, J.M. (1994). Cisplatin-DNA adducts are molecular decoys for the ribosomal RNA transcription factor hUBF (human upstream binding factor). Proc. Natl Acad. Sci. USA 91, 5672-5676.
55. Vichi, P., et al., & Egly, J.-M. (1997). Cisplatin- and UV-damaged DNA lure the basal transcription factor TFIID/TBP. EMBO J. 16, 7444-7456.
56. Kingston, R.E., Chen, C.A., Okayama, H. & Rose, J.K. (1997). Calcium phosphate transfection. In Current Protocols in Molecular Biology. (Ausubel, F.M., ed.), pp. 9.1.4-9.1.11, John Wiley & Sons, Inc., New York.
57. Shackleford, G.M. & Varmus, H.E. (1987). Expression of the protooncogene int-1 is restricted to postmeiotic male germ cells and the neural tube of mid-gestational embryos. Cell 50, 89-95.
58. Greenberg, M.E. & Bender, T.P. (1997). Identification of newly transcribed RNA. In Current Protocols in Molecular Biology. (Ausubel, F.M., ed.), pp. 4.10.1-4.10.11, John Wiley & Sons, Inc., New York.